Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar 5:26:101469.
doi: 10.1016/j.ajoc.2022.101469. eCollection 2022 Jun.

A case of IgG4-related conjunctival tumor with severe systemic allergy treated with antibodies against cytokine receptors

Atsuki Fukushima  1 , Sachiko Maruoka  1 , Hitoshi Tabuchi  1
Affiliations
Case Reports

A case of IgG4-related conjunctival tumor with severe systemic allergy treated with antibodies against cytokine receptors

Atsuki Fukushima et al. Am J Ophthalmol Case Rep. .

Abstract

Purpose: To present a case of IgG4-related conjunctival tumor in which anti-IL-5 receptor alpha-chain and anti-IL-4 receptor alpha-chain antibodies were administered for eosinophil sinusitis and severe bronchial asthma, but conjunctivitis could not be controlled.

Observations: A 53-year-old male patient started to receive anti-IL-5 receptor alpha chain antibody to treat eosinophilic sinusitis and eosinophilic severe bronchial asthma. Several months later, proliferative changes of the right palpebral conjunctiva appeared and were treated with tacrolimus and betamethasone eye drops. However, the findings gradually worsened and the right upper palpebral conjunctiva remained exposed. Exposed tissue was resected and histopathological examinations revealed the presence of IgG4 positive cells (10>/400HPF). Anti-IL-5 receptor alpha chain antibody treatment was stopped and changed to prednisolone. The findings improved and anti-IL-4 receptor alpha chain antibody was added to control eosinophilic sinusitis and eosinophilic severe bronchial asthma. The lesions worsened when the prednisolone was reduced under treatment with anti-IL-4 receptor alpha-chain antibody.

Conclusions and importance: In this case, the proliferative changes could not be suppressed by treatment targeting IL-5R receptor alpha-chain and IL-4R receptor alpha-chain, suggesting that the patient had VKC-like severe allergic conjunctivitis as a manifestation of IgG4-related disease. Additionally, it should be noted that if the severe conjunctivitis cannot be suppressed by treatment with immunosuppressive eye drops or various systemic biological agents, the conjunctivitis may be a manifestation of IgG4 related disease.

Keywords: Anti-IL-4R receptor alpha-chain antibody; Anti-IL-5R receptor alpha-chain antibody; IgG4 related disease; Vernal keratoconjunctivitis.

PubMed Disclaimer

Conflict of interest statement

The following authors have no financial disclosures: AF, SM and HT.

Figures

Fig. 1
Fig. 1
Slit photographs at the initial visit (June 2019). A: right eye, B: left eye.
Fig. 2
Fig. 2
Photographs of the right upper palpebral conjunctiva (January 2020). Note that the right upper palpebral conjunctiva remained exposed.
Fig. 3
Fig. 3
Photographs of histopathological examinations for the surgically resected right upper palpebral conjunctiva (February 2021). A: HE staining, x40, B: anti-CD3 immunohistochemistry, x100, C: anti-CD79a immunohistochemistry, x100, D: anti-IgG immunohistochemistry, x400, E: anti-IgG4 immunohistochemistry, x400.
See this image and copyright information in PMC

References

    1. FitzGerald J.M., Bleecker E.R., Nair P., et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. - PubMed
    1. Bledsoe J.T., Della-Torre E., Rovati L., Deshpande V. IgG4-related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach. APMIS. 2018;126(6):459–476. - PubMed
    1. Werfel T., Allam J.P., Biedermann T., et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. - PubMed
    1. Takahashi H., Hamano M., Takizawa S., Tatewaki W., Shibata A. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1988;28(3):162–166. - PubMed
    1. Baker S.K., Strickland S. A critical role for plasminogen in inflammation. J Exp Med. 2020;217(4) - PMC - PubMed

Publication types

LinkOut - more resources